Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (JANX)

CUSIP: 47103J105

Q3 2026 13F Holders as of 30 Sep 2026

Holder snapshot 6 signals
Share change
+18,851
SEC-reported price per share
$17.28
Number of holders
5
Value change
+$325,790
Number of buys
5
Number of sells
1
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
60,419,303

Security key

47103J105

Report period

Q3 2026

Institutions

5

Top holders

5

Ownership snapshot

Top reported holders of JANX - Janux Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
30 Jun 2026
13D/G 3/4/5 13F Lead comparable stake: 20% 13D/G row: RA CAPITAL MANAGEMENT, L.P. Showing 1-6 of 15 holder rows.

Quick read

RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 20%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership Top 5
RA CAPITAL MANAGEMENT, L.P. 20%
BlackRock, Inc. 6.7%
Prosight Management, LP 5.3%
Paradigm Biocapital Advisors LP 4.9%
Adage Capital Management, L.P. 4.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
RA CAPITAL MANAGEMENT, L.P.
13D/G 3/4/5 13F
Director, 10%+ Owner · Company
20%
$383,922,060
11,971,377 shares
$0 06 Mar 2025
BlackRock, Inc.
13F 13D/G
Company
6.7%
from 13D/G
$94,228,481
6,134,667 shares
— 30 Jun 2026
Prosight Management, LP
13F 13D/G
Company · W. Lawrence Hawkins
5.3%
from 13D/G
$58,436,828
3,804,481 shares
— 30 Jun 2026
Paradigm Biocapital Advisors LP
13D/G
4.9%
$73,444,489
2,920,258 shares
-$14,982,559 30 Jun 2025
Adage Capital Management, L.P.
13D/G
4.3%
$63,503,750
2,525,000 shares
-$13,499,262 30 Jun 2025
FMR LLC
13F 13D/G
Company
4.2%
from 13D/G
$37,060,986
2,412,825 shares
— 30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
5
Shares
90,243
Rows available
5
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders
193
Q3 2026 holders
5
Holder diff
-188
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .